• Cancer and Oncology
• 30 min
  1. Endometrial cancer: integrating molecular insights into personalized care

  • Dr. Gemma Eminowicz
• 30 min
  2. The molecular basis of cancer metastasis: molecular mechanisms of epithelial-mesenchymal transition in tumor metastasis

  • Prof. Jing Yang
• 26 min
  3. The molecular basis of cancer metastasis: multi-step metastasis process and anti-metastasis therapeutic development

  • Prof. Jing Yang
• 28 min
  4. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours

  • Dr. Else Marit Inderberg
• 36 min
  5. Mode of action of T cells engineered with CAR or TCR for cancer treatment

  • Prof. Sebastian Kobold
• 37 min
  6. Immunotherapy: insights from advanced disease

  • Dr. Sara M. Tolaney
• 35 min
  7. Recent advances in the field of non-coding RNAs in cancer

  • Prof. George Calin
  • Dr. Maitri Shah
• 34 min
  8. How tumor-microenvironment interactions drive or inhibit metastasis

  • Prof. Isaac P. Witz
• 23 min
  9. A novel cancer therapy to stimulate oncogenic ERK signalling

  • Prof. Reiko Sugiura
• 37 min
  10. MRD-driven multiple myeloma treatment: next step forward

  • Prof. Ola Landgren
• 29 min
  11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention

  • Dr. Koorosh Korfi
  • Prof. Jude Fitzgibbon
• 37 min
  12. Immunotherapy in lung cancer

  • Dr. Mark M. Awad
• 35 min
  13. Preservation of fertility in cancer patients: the impact of chemotherapy

  • Prof. Kutluk H. Oktay
• 41 min
  14. Preservation of fertility in cancer patients: BRCA mutations, ovarian tissue cryopreservation and transplantation, and pharmacological treatments in fertility preservation

  • Prof. Kutluk H. Oktay
• 47 min
  15. Solution proposed to a 2000 year old problem in oncology

  • Dr. Michael Retsky
• Clinical Practice
• 52 min
  16. Comprehensive sickle cell care in the era of gene therapy

  • Prof. Sophie Lanzkron
• 36 min
  17. Stillbirth: diagnosis, investigation and aftercare

  • Prof. Alexander E. P. Heazell
• 30 min
  18. Analyzing the medical relevance of skin care trends

  • Prof. Zoe Draelos
• 42 min
  19. Genetic counseling: preconception, prenatal, perinatal

  • Prof. Aubrey Milunsky
• 26 min
  20. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  21. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 40 min
  22. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 33 min
  23. Mitochondrial diseases: an update

  • Dr. Ayesha Saleem
• 31 min
  24. Hemophilia A

  • Dr. Snejana Krassova
• 32 min
  25. Artificial intelligence in medicine: history & state of the art

  • Prof. John Fox
• 27 min
  26. Artificial intelligence in medicine: scaling & deployment of applications

  • Prof. John Fox
• 36 min
  27. Recent advances in diagnosis and interventions in ophthalmology

  • Dr. Rebecca Kaye
  • Prof. Andrew Lotery
• Gastroenterology
• 34 min
  28. Building implantable human liver tissue from pluripotent stem cells

  • Prof. David C. Hay
• 35 min
  29. Microbiome therapies to treat gastrointestinal diseases

  • Dr. Patricia Bloom
• 46 min
  30. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI

  • Prof. James H. Lewis
• 26 min
  31. Drug-induced liver injury: risk factors and drug development in DILI

  • Prof. James H. Lewis
• 39 min
  32. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI

  • Prof. James H. Lewis
• 46 min
  33. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• Immunology
• 33 min
  34. Next-generation RNA vaccines

  • Dr. Anna Blakney
• 40 min
  35. Harnessing the immune system for cancer therapy

  • Dr. Raghav Sundar
• 51 min
  36. Rac-enhanced CAR immunotherapy: RaceCAR

  • Prof. Denise Montell
• 38 min
  37. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1

  • Prof. Kevin Harrington
• 19 min
  38. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2

  • Prof. Kevin Harrington
• 56 min
  39. Drug allergy: new knowledge

  • Prof. Mariana C. Castells
• 32 min
  40. Biologics as a treatment strategy in food allergy

  • Prof. Sayantani B. Sindher
• 42 min
  41. B cells at the crossroads of autoimmune diseases

  • Dr. Xiang Lin
• 48 min
  42. Studying immune responses “one cell at a time”

  • Dr. Mir-Farzin Mashreghi
• 43 min
  43. Mathematical modeling in immunology

  • Prof. Ruy M. Ribeiro
• 18 min
  44. Therapeutic antibody development

  • Prof. Dr. Katja Hanack
• 25 min
  45. Understanding treatment coverage in mass drug administrations

  • Dr. Margaret Baker
• 39 min
  46. The thymus and T cell development: a primer

  • Prof. Georg Holländer
• 40 min
  47. The potential of CAR T cells for the treatment of autoimmune diseases

  • Dr. Marko Radic
• Infectious Diseases
• 17 min
  48. HCV resistance

  • Prof. John Dillon
• 36 min
  49. The Global Virus Network: collaboration to address pandemic and regional threats

  • Prof. Sten H. Vermund
• 28 min
  50. New concepts in the management of CAP: a focus on severe illness - treatment and therapies

  • Prof. Michael S. Niederman
• 24 min
  51. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens

  • Prof. Michael S. Niederman
• 46 min
  52. CRISPR-based suppression drives for vector control

  • Prof. Andrea Crisanti
• 39 min
  53. HIV cure: harnessing innate and adaptive strategies

  • Prof. Luis Montaner
• Cardiovascular, Metabolism & Nutrition
• 29 min
  54. Cow’s milk allergy: the future

  • Dr. Carina Venter
• 17 min
  55. Cow's milk allergy: management

  • Dr. Carina Venter
• 50 min
  56. Moving from GWAS hits to functional variants

  • Prof. Steve Humphries
• 44 min
  57. X-linked hypophosphataemia: genetics, diagnosis and management

  • Prof. Thomas O. Carpenter
• 37 min
  58. What is new in type 1 diabetes?

  • Prof. Åke Lernmark
• 35 min
  59. Current concepts for the management of patients with osteoporosis

  • Dr. Michael Lewiecki
• 29 min
  60. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 38 min
  61. Peptide YY (PYY) in obesity and diabetes

  • Dr. Nigel Irwin
• Microbiology
• 39 min
  62. Vaccines and the fight against antimicrobial resistance 1

  • Dr. Annaliesa S. Anderson
• 40 min
  63. Vaccines and the fight against antimicrobial resistance 2

  • Dr. Annaliesa S. Anderson
• 30 min
  64. Vaccines as a weapon against antibiotic resistance

  • Dr. Pumtiwitt McCarthy
• 24 min
  65. PathoLive: pathogen detection while sequencing

  • Dr. Simon Tausch
• 37 min
  66. Translating microbiome research to clinics: trends, directions and challenges

  • Prof. Raj Eri
• 37 min
  67. Successes and failures with vaccines

  • Prof. Stanley Plotkin
• 30 min
  68. Immunology, the microbiome and future perspectives

  • Prof. Sheena Cruickshank
• 22 min
  69. Impact of the HPV vaccine programme – a changing landscape

  • Dr. Kevin Pollock
• Neurology and Neuroscience
• 23 min
  70. Immunology of the peripheral nervous system: the inflammatory neuropathies

  • Dr. Simon Rinaldi
• 52 min
  71. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond

  • Prof. Stephen Waxman
• 48 min
  72. Advances in the diagnosis and treatment of tardive dyskinesia

  • Prof. Emeritus Stanley N. Caroff
• 31 min
  73. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation

  • Prof. Charles S. Cox, Jr.
• 57 min
  74. Cardiovascular involvement in Parkinson’s disease

  • Dr. David S. Goldstein
• 22 min
  75. Molecular brain imaging (PET) in diseases with dementia

  • Prof. Karl Herholz
• 34 min
  76. Current thinking in pain medicine and some thoughts on back pain

  • Dr. Nick Hacking
• 27 min
  77. Bioelectronic medicine: immunomodulation by vagus nerve stimulation

  • Prof. Paul Peter Tak
• 31 min
  78. Developments & future directions in the management of chronic pain

  • Prof. Simon Haroutounian
• 41 min
  79. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia

  • Prof. Judith Gault
• 39 min
  80. Parkinson’s at 200 years: an update on Parkinson’s research in 2017

  • Prof. Patrick A. Lewis
• 43 min
  81. Alzheimer's disease: where are we up to?

  • Prof. John Hardy
• Pharmaceutical Sciences
• 30 min
  82. Peptide-drug conjugates as therapeutic modality in drug development 1

  • Dr. Syed Faheem Askari Rizvi
• 27 min
  83. Peptide-drug conjugates as therapeutic modality in drug development 2

  • Dr. Syed Faheem Askari Rizvi
• 38 min
  84. Pharmacokinetics, -dynamics and dosing considerations in children

  • Prof. Dr. Karel Allegaert
• 24 min
  85. Why in vitro permeation test – and not in vivo?

  • Prof. Howard Maibach
• 48 min
  86. The future of plasma-derived medicinal products (PDMP)

  • Dr. Daniele Focosi
• 37 min
  87. RNA therapeutics: clinical applications and methods of delivery

  • Prof. John P. Cooke
• 40 min
  88. Recent advances in the development of gene delivery technologies

  • Dr. Takis Athanasopoulos
• 32 min
  89. Preclinical translation of mesenchymal stem cell therapies

  • Dr. Peter Childs
• 20 min
  90. Modulating gene expression to treat diseases

  • Dr. Navneet Matharu
• 38 min
  91. Accelerating drug discovery with machine learning and AI

  • Dr. Olexandr Isayev
• 44 min
  92. Emerging big data in medicinal chemistry: promiscuity analysis as an example

  • Prof. Dr. Jürgen Bajorath
  • Dr. Ye Hu
• 49 min
  93. Binding kinetics in drug discovery

  • Dr. Rumin Zhang
• 49 min
  94. Modeling of antibody-drug conjugate pharmacokinetics

  • Dr. Dhaval K. Shah
• 35 min
  95. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• 51 min
  96. Current challenges in the design of antibody-drug conjugates

  • Prof. L. Nathan Tumey
• 27 min
  97. Inorganic nanostructured interfaces for therapeutic delivery

  • Prof. Tejal Desai
• 32 min
  98. Latest development in therapy-related autophagy research

  • Dr. Vignir Helgason
• Respiratory Diseases
• 29 min
  99. Diagnosis of tuberculosis and drug resistant tuberculosis 1

  • Dr. Daniela Cirillo
• 32 min
  100. Diagnosis of tuberculosis and drug resistant tuberculosis 2

  • Dr. Daniela Cirillo
• 29 min
  101. Respiratory syncytial virus vaccination

  • Prof. Peter Openshaw
• 22 min
  102. Advances in gene therapy for respiratory diseases 1

  • Prof. John F. Engelhardt
• 41 min
  103. Advances in gene therapy for respiratory diseases 2

  • Prof. John F. Engelhardt
• 37 min
  104. Asthma

  • Prof. William Busse
  • Dr. Amanda McIntyre
• 45 min
  105. New drugs for asthma

  • Prof. Peter Barnes
• 29 min
  106. CompEx asthma: a novel composite exacerbation endpoint

  • Dr. Carla A. Da Silva
• 42 min
  107. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• Archived Lectures *These may not cover the latest advances in the field
• 34 min
  108. The role of exosomes in multiple myeloma development & drug resistance

  • Prof. Eline Menu
• 40 min
  109. AI and big data in drug discovery

  • Mr. Ed Addison

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. Background and molecular classification in EC
4. Endometrial cancer
5. Treatment for recurrent/metastatic EC
6. Risk stratification in early-stage
7. Risk stratification in early-stage disease
8. Risk stratification- molecular classification
9. Categorising “double classifiers”
10. Other considerations regarding the importance of biomarker testing
11. Biomarker testing in the era of molecular classifications: Focus on dMMR
12. MLH1 promotor hypermethylation and Lynch testing
13. Risk stratification
14. Molecular classification as prognostic marker
15. Molecular classification as a prognostic marker for EC
16. Prognostic classification of EC using NGS panel
17. ProMisE molecular classifier
18. ProMisE outcomes
19. Molecular-based classification of EC
20. Prognostic value of molecular classification
21. L1CAM expression in high-risk EC
22. Molecular classification as prognostic marker and implications
23. Molecular classification as predictive marker
24. PORTEC 3
25. PORTEC 3 – molecular markers
26. RUBY trial
27. RUBY – outcomes
28. KEYNOTE-868/ NRG-GY018
29. KEYNOTE-868 - PFS
30. DUO-E trial
31. DUO-E trial –dMMR
32. pMMR biomarker-known subpopulation
33. pMMR subpopulation: CP + durvalumab vs. CP
34. pMMR subpopulation: CP + durvalumab + Olaparib vs. CP
35. Phase 3 randomised, double-blind study
36. Immunotherapy in dMMR patients: Evidence from the adjuvant setting
37. Hormonal therapy
38. Prognostic impact of molecular classification in fertility-sparing treatment
39. Molecular classification predicts radiotherapy response
40. GOG-258 outcomes according to ProMiSE
41. Molecular classification as predictive marker & treatment response
42. Integrating molecular classification into clinical practice
43. Essential clinical requirements
44. British Association of Gynaecological Pathologists guidance on POLE testing
45. ESGO/ESTRO/ESP guidelines for patients with EC
46. 2023 FIGO staging of cancer of the endometrium (1)
47. Future pathways
48. 2023 FIGO staging of cancer of the endometrium (2)
49. RAINBO trial
50. Potential future pathway – IO single agent
51. DOMENICA trial
52. Future treatment pathways
53. Thank you and financial disclosures

Topics Covered

• Background and molecular classification in endometrial cancer
• Molecular classification as prognostic marker
• Molecular classification as predictive marker for treatment response
• Integrating molecular classification into clinical practice
• Future pathways

Links

Series:

• Periodic Reports: Advances in Clinical Interventions and Research Platforms

Categories:

• Cancer
• Cell Biology
• Clinical Practice

Therapeutic Areas:

• Gynaecology & Obstetrics
• Oncology

Talk Citation

Publication History

• Published on October 30, 2025

Financial Disclosures

• Dr. Gemma Eminowicz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.